Rituximab + Chemo Ups Survival in Pediatric B-Cell Non-Hodgkin Lymphoma
THURSDAY, June 4, 2020 -- For children and adolescents with high-grade, high-risk, mature B-cell non-Hodgkin lymphoma, rituximab added to standard lymphomes malins B (LMB) chemotherapy prolongs event-free survival, according to a study published in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 4, 2020 Category: Pharmaceuticals Source Type: news
Phase III results show rituximab excels against pediatric Burkitt lymphoma
(University of Colorado Anschutz Medical Campus) Results of the phase III Inter-B-NHL-ritux 2010 clinical trial reported today in the New England Journal of Medicine show 95 percent three-year survival for pediatric patients with advanced B-cell non-Hodgkin lymphoma treated with the addition of anti-cancer immunotherapy rituximab to standard chemotherapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 3, 2020 Category: International Medicine & Public Health Source Type: news
Long-Term Rituximab May Aid in Antibody-Associated Vasculitis
TUESDAY, June 2, 2020 -- For patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), extended therapy with rituximab is associated with a reduced incidence of antineutrophil cytoplasmic antibody-associated vasculitis... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 2, 2020 Category: Pharmaceuticals Source Type: news
Rituximab Promising in New-Onset Myasthenia Gravis Rituximab Promising in New-Onset Myasthenia Gravis
New research suggests rituximab is safer and more effective than immunosuppressants for myasthenia gravis, especially in new-onset disease.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - May 11, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Rituximab Offers No Extra Benefit to Induction Chemo in ALL Rituximab Offers No Extra Benefit to Induction Chemo in ALL
Patients with B-precursor acute lymphoblastic lymphoma may not benefit from adding rituximab to standard induction chemotherapy, suggests UK trial data that also identified novel genetic risk factors.Medscape News UK (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 8, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
E1912 trial leads to FDA approval of ibrutinib-rituximab combo for untreated CLL
(ECOG-ACRIN Cancer Research Group) Patients aged 70 or younger with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma have a new treatment option -- a combination of the targeted agent ibrutinib with the immunologic agent rituximab. The FDA has approved the combination based on data from E1912, a phase 3 trial that showed this combination provides better leukemia control, prolongs life, and has fewer side effects compared to standard care. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 29, 2020 Category: Cancer & Oncology Source Type: news
Janssen Announces Submission of Two Applications to U.S. FDA Seeking Approval of SIMPONI ARIA ® (golimumab) for the Treatment of Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis
HORSHAM, PA, April 24, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of two supplemental Biologics License Applications (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of SIMPONI ARIA® (golimumab) for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) and juvenile psoriatic arthritis (jPsA), in patients two years of age and older in combination with methotrexate. If approved for these indications, SIMPONI ARIA would be the first anti-tumor necrosis factor (TNF)-alpha biologic agent administered by intravenous infusion available...
Source: Johnson and Johnson - April 24, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
FDA Approves Ibrutinib Plus Rituximab Combo for CLL FDA Approves Ibrutinib Plus Rituximab Combo for CLL
This combination of targeted agents showed better progression-free survival than a standard chemoimmunotherapy regimen in patients with newly diagnosed chronic lymphocytic leukemia.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 22, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
U.S. FDA Approves IMBRUVICA ® (ibrutinib) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
HORSHAM, Pa., April 21, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of IMBRUVICA® (ibrutinib) in combination with rituximab for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are new to therapy. The approval is based on positive results from the landmark Phase 3 E1912 study that was designed and conducted by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and sponsored by the National Cancer Institute, part of the National Institutes of Health. Today’s milestone mar...
Source: Johnson and Johnson - April 22, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
FDA Approves Ibrutinib Combined with Rituximab for Patients with CLL/SLL
The FDA approved ibrutinib in combination with rituximab for the initial treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - April 22, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
FDA Approves Imbruvica (ibrutinib) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
NORTH CHICAGO, Ill., April 21, 2020– AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved the use of Imbruvica® (ibrutinib) in combination with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 21, 2020 Category: Drugs & Pharmacology Source Type: news
Rituximab for Maintenance of Remission in ANCA Vasculitis Rituximab for Maintenance of Remission in ANCA Vasculitis
This article provides a summary of new guidelines regarding the use of rituximab as a treatment option in remission maintenance of ANCA-associated vasculitis.Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 17, 2020 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
Russian antitumor drugs first time registered in Europe
(BIOCAD) Two BIOCAD products, Acellbia (INN: rituximab) and Herticad (INN: trastuzumab), received the first European registration certificate in Bosnia and Herzegovina. Registration was received with the support of ICM d.o.o partner and is valid for 5 years. The first deliveries shall start in June 2020. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 1, 2020 Category: Cancer & Oncology Source Type: news
Patients and RWE: Is this the year?
The long-hyped redefinition of healthcare through wearable tech has been … well, long hyped. Early projects, such as Apple HealthKit and Fitbit, were undoubtably important in redefining ‘the possible’ but they haven’t yet achieved transformative application.  Much has been written on why the philosophy that has driven the astonishing success of consumer technology doesn ’t translate to healthcare and when we look at the state of innovation in 2020, many of these structural issues remain.   As Emily Cerciello, Associate Director, Digital Health and Engagement at the Crohn ' s& Colitis Foundation states, â€...
Source: EyeForPharma - March 26, 2020 Category: Pharmaceuticals Authors: Tom Disley Source Type: news
Patients and RWE: Is this the year?
The long-hyped redefinition of healthcare through wearable tech has been … well, long hyped. Early projects, such as Apple HealthKit and Fitbit, were undoubtably important in redefining ‘the possible’ but they haven’t yet achieved transformative application.  Much has been written on why the philosophy that has driven the astonishing success of consumer technology doesn ’t translate to healthcare and when we look at the state of innovation in 2020, many of these structural issues remain.   As Emily Cerciello, Associate Director, Digital Health and Engagement at the Crohn ' s& Colitis Foundation states, â€...
Source: EyeForPharma - March 26, 2020 Category: Pharmaceuticals Authors: Tom Disley Source Type: news
